Protalix Biotherapeutics Inc PLX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2010-09-06 |
| Shares Out. | 80,570,000 |
| Website | protalix.com/ ↗ |
| Phone | 12016969345 |
| Employees | 226 |
| Revenue | $33.8M |
| Gross Profit | $29.6M |
| Net Income | $18.3M |
| Free Cash Flow | $13.0M |
| Total Assets | $102.3M |
| Total Liabilities | $35.1M |
| Equity | $67.2M |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix Biotherapeutics Inc is a publicly traded company under the ticker symbol PLX on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
5 analysts (2026-07-01)